On August 16, 2022, the Board of Directors of Schrödinger, Inc. appointed Geoffrey Porges as Executive Vice President of the Company, effective upon the commencement of his employment with the Company on August 18, 2022 (the “Effective Date”). In connection with his appointment as Chief Financial Officer, Dr. Porges will serve as the Company's principal financial officer. As a result of Dr. Porges' appointment as Chief Financial Officer, Jenny Herman, the Company's Senior Vice President, Finance and Corporate Controller, will cease to serve as the Company's interim principal financial officer.

Ms. Herman will continue to serve as the Company's principal accounting officer. Prior to joining the Company, Dr. Porges, age 61, served as Vice Chairman of SVB Securities LLC (formerly known as SVB Leerink), the investment banking subsidiary of SVB Financial Group (“SVB Securities”), and as Venture Partner of SVB Capital, the private equity arm of SVB Financial Group, in each case, from January 2022 to August 2022. Prior to his role as Vice Chairman, Dr. Porges held positions of increasing responsibility at SVB Securities, including serving as Senior Managing Director from February 2019 to January 2022 and as Senior Biopharmaceuticals Analyst and Director of Therapeutics Research from November 2015 to February 2019.

Prior to joining SVB Securities, Dr. Porges spent 13 years at Alliance Bernstein, an investment management firm, most recently serving as Managing Director. Prior to joining Alliance Bernstein, Dr. Porges was Chief Operating Officer and Head of Health, Medical and Biotechnologies Programs at BTG Plc, a pharmaceutical company, from 1999 to 2002 and was a member of the board of directors of Acambis plc from 2001 to 2003. Dr. Porges received a Bachelor of Medicine and a Bachelor of Surgery from the University of Sydney and an M.B.A. from Harvard Business School.